Biopharmaceutical Company Makes Headlines For Potential New Drug

The world of medicine is constantly evolving, and one company at the forefront of this evolution is Trevena, Inc. (NASDAQ: $TRVN). A biopharmaceutical company with a focus on developing innovative therapies, Trevena recently made headlines with the publication of their research in the PLOS ONE journal. The study, titled "Efficacy, safety, and side effects of oliceridine in acute postoperative pain, a protocol for a systematic review and meta-analysis," dives into the potential of a promising new drug, Oliceridine. $Trevena(TRVN.US)$